TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04412733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Pulsed Ultrasound
Description: Patients in pulsed ultrasound group received pulsed ultrasound treatment (frequency: 1000 kHz, intensity: 0.5w/cm2, on-off ratio: 1:2). Pulsed ultrasound treatment were applied with 5-cm2 head Enraf-Nonius Sonopuls 434 ultrasound device.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Ultrasound
Description: Control group received sham ultrasound treatment
Study: NCT02728414

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics
Description: the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: placebo
Description: the patients in this arm will receive placebo intervention
Study: NCT01509677

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast
Description: 500 μg tablet, once daily, oral administration in the morning after breakfast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet, once daily, oral administration in the morning after breakfast
Study: NCT02033590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodegradable (purified) surgical silk scaffold
Study: NCT00944736

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: VSL#3
Description: 1 packet BID

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 inactive packet BID
Study: NCT00358332

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMP2.1/AS02A
Description: FMP2.1 will be reconstituted in AS02A adjuvant. Dosages: 10, 25, or 50 mcg of FMP2.1 or 0.1, 0.25 or 0.5 mL of FMP2.1/AS02A administered by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMP2.1/AS02A
Description: FMP2.1 will be reconstituted in AS02A adjuvant. Dosages: 10, 25, or 50 mcg of FMP2.1 or 0.1, 0.25 or 0.5 mL of FMP2.1/AS02A administered by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMP2.1/AS02A
Description: FMP2.1 will be reconstituted in AS02A adjuvant. Dosages: 10, 25, or 50 mcg of FMP2.1 or 0.1, 0.25 or 0.5 mL of FMP2.1/AS02A administered by intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies vaccine (RabAvert)
Description: RabAvert, white, freeze-dried vaccine for reconstitution with diluent. Dosage: 1.0 mL of rabies vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies vaccine (RabAvert)
Description: RabAvert, white, freeze-dried vaccine for reconstitution with diluent. Dosage: 1.0 mL of rabies vaccine.
Study: NCT01965054

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil Supplement Group
Description: 1 liquid gel pill (440mg omega-3 fatty acids from fish oil) taken daily, enrollment to delivery
Study: NCT01739660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegloticase
Description: a single 8 mg iv (in the vein) dose before hemodialysis session
Study: NCT00358332

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies vaccine (RabAvert)
Description: RabAvert, white, freeze-dried vaccine for reconstitution with diluent. Dosage: 1.0 mL of rabies vaccine.
Study: NCT02510651

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Melanocyte-keratinocyte suspension
Description: Treatment of non-segmental vitiligo by CO2 laser followed by melanocyte-keratinocyte suspension.
Study: NCT02199886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBH 1
Description: labeled with eight to ten millicurie of 131I
Study: NCT02198963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypochlorous acid solution 106 mg/L
Description: test product
Study: NCT01757223

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdVEGF-All6A+
Description: We will administer AdVEGF-All6A+, an adenovirus vector carrying the genetic material for human vascular endothelial growth factor to the ischemic myocardium of individuals with diffuse coronary artery disease.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdVEGF-All6A+
Description: We will administer AdVEGF-All6A+, an adenovirus vector carrying the genetic material for human vascular endothelial growth factor to the ischemic myocardium of individuals with diffuse coronary artery disease.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdVEGF-All6A+
Description: We will administer AdVEGF-All6A+, an adenovirus vector carrying the genetic material for human vascular endothelial growth factor to the ischemic myocardium of individuals with diffuse coronary artery disease.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdVEGF-All6A+
Description: We will administer AdVEGF-All6A+, an adenovirus vector carrying the genetic material for human vascular endothelial growth factor to the ischemic myocardium of individuals with diffuse coronary artery disease.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdNull
Description: AdNull is an adenovirus vector identical to AdVEGF-All6A+, except that it does not encode for a transgene.
Study: NCT04615975

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic diet with phytoextracts
Description: Patients were provided with an individualized nutritional ketogenic plan during hospitalization
Study: NCT03796754

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: YoBEKA
Description: The teachers and students of the YoBEKA study arm receive a guided YoBEKA practice from an experienced YoBEKA trainer during the regular 4 month intervention period. The YoBEKA program is based on a combination of different, easy to perform exercises appropriate to the school situation, consisting of postures, verses for speech, song and movement, affirmations in movement to promote balance and coordination, and various rest and silence exercises to promote body awareness and relaxation techniques. The teaching is ideologically neutral and without religious background. The participating teachers receive an initial two-hour YoBEKA introductory course. Every 2 weeks there is a one to two-hour training course. The pedagogical specialists are supported once a week by an experienced YoBEKA trainer. The teachers are encouraged to integrate the learned exercises independently and regularly into their everyday school life.
Study: NCT04127799

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospital-Community-Family-Care Management Platform Online
Description: Subjects with Hospital-Community-Family-Care Management Platform online and those with the clinic follow up. In the program, participants were educated on the use of smart health-tracking devices and mobile application (APP) to collect and upload comprehensive data elements related to the risk of AF self-care management. They were also instructed to send text messages, view notifications, and receive individualized guidance on the mobile APP. The general practitioners viewed index of each participant on mobile APP and provided primary care periodically, and cardiologists in regional central hospital offered remote guidance and management if necessary. Outcomes assessed included accomplishments of the program, usability and satisfaction, engagement with the intervention, and changes of AF-related health behaviors.
Study: NCT04071730

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immulina Dietary Supplementation
Description: Immulina Dietary Supplementation is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Immulina Dietary Supplementation
Description: Immulina Dietary Supplementation is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.
Study: NCT02964962

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 29 mm LOTUS Edge™ Valve System
Description: Transcatheter aortic valve replacement
Study: NCT02066233

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EG Scan II (transnasal endoscopy)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EG Scan II (transnasal endoscopy)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Endoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Endoscopy
Study: NCT03963791

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eggshell powder gel
Description: Eggshell powder gel produced from chicken eggs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eggshell powder gel
Description: Eggshell powder gel produced from chicken eggs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CPP-ACP crème
Description: A water-based, sugar-free topical cream containing Recaladent (CCP-ACP) which is derived from the milk protein.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPP-ACP crème
Description: A water-based, sugar-free topical cream containing Recaladent (CCP-ACP) which is derived from the milk protein.
Study: NCT00628992

Intervention type: OTHER
Group type: OTHER
Intervention: No specific intervention, standard therapy serving as a control group, passive mobilization of the legs
Description: Muscular rehabilitation of the leg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrical stimulation of the thigh
Description: Muscular rehabilitation of the leg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cycloergometer training
Description: Muscular rehabilitation of the leg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrical stimulation of the thigh and cycloergometer training
Description: Muscular rehabilitation of the leg
Study: NCT03267186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00314015

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Evaluation of the success rate of implants
Description: Evaluation of the success rate of implants will be followed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires will be used
Study: NCT02198963

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% (w/v) Sodium Lauryl Sulfate
Description: positive control

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Physiological Saline, USP
Description: negative control
Study: NCT00736437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME-609
Description: Cream applied topically 6 times daily over the UVR exposed area

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Treatment applied 6 times daily over the UVR exposed area
Study: NCT03719352

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo Gastrocnemius dry needling
Description: Simulate pain with de plastic needle guard in the gastrocnemius muscle
Study: NCT00103220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SJG-136
Description: Given IV
Study: NCT03886883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise induced hypoalgesia (EIH)
Description: An EIH response was induced by a 3-minute isometric contraction of the hand flexor muscles at 25% of maximal voluntary contraction (MVC).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static stretch (SS)
Description: Two bouts of 30 seconds of static stretching (SS) of the knee flexors.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Rest
Description: The participants rested in a seated position for 10 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conditioned pain modulation (CPM)
Description: A CPM response was induced by way of the cold pressor test.
Study: NCT01967914

Intervention type: OTHER
Intervention: PVI
Description: Measurement of PVI (plethysmography variability index)
Study: NCT00588588

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopy
Description: Bronchoscopy procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clinical pulmonary infection score (CPIS)
Description: Calculate CPIS
Study: NCT01883349

Intervention type: PROCEDURE
Intervention: Kidney Transplant
Description: Kidney Transplant Surgery

Intervention type: OTHER
Intervention: No kidney transplant
Description: The control group was made up of subjects without ESRD and were not on the renal transplantation waitlist.
Study: NCT03762044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity-oriented Proprioceptive Antiedema Therapy (TAPA)
Description: * Health education / patient empowerment.~* Neurodynamic activities oriented to ADL.~* Proprioceptive neuromuscular facilitation exercises oriented to ADL.~* Self-adherent self-adhesive antiedema of low compression.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complete Decongestive Therapy (CDT)
Description: * Skin care.~* Kinesitherapy~* Manual lymphatic drainage (MLD)~* Multilayer bandage.~The maintenance phase is based on self-care and the use of compression garments.
Study: NCT04614948

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: Ad26.COV2.S vaccine will be administered on Day 1 and Day 57 in the double-blind phase. At unblinding visit Ad26.COV2.S vaccine will be administered to participants at Day 57 who have not yet received second vaccination and in newly enrolled participants as either single dose on Day 1 or two doses on Day 1 and Day 57. Single dose of Ad26.COV2.S vaccine will also be administered to participants initially receiving placebo. Single booster dose of Ad26.COV2.S vaccine will be given to participants in the open label phase who have received only a single vaccination with Ad26.COV2.S.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Ad26.COV2.S
Description: Ad26.COV2.S vaccine will be administered on Day 1 and Day 57 in the double-blind phase. At unblinding visit Ad26.COV2.S vaccine will be administered to participants at Day 57 who have not yet received second vaccination and in newly enrolled participants as either single dose on Day 1 or two doses on Day 1 and Day 57. Single dose of Ad26.COV2.S vaccine will also be administered to participants initially receiving placebo. Single booster dose of Ad26.COV2.S vaccine will be given to participants in the open label phase who have received only a single vaccination with Ad26.COV2.S.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as IM injection on Day 1 and Day 57.
Study: NCT01365312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol lock
Description: Placement of 0.5 cc 70% ethanol, every 72 hours, for 15 minutes, into PICC lines randomized to ethanol intervention

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Heparinized saline
Description: 0.5 cc heparinized saline to be placed once every 72 hours for 15 minutes, in PICC lines randomized to placebo
Study: NCT02329626

Intervention type: DEVICE
Intervention: PET CT 18 FDG
Description: Positron emission tomography with 2-deoxy-2-\[fluorine-18\]fluoro- D-glucose integrated with computed tomography.~This intervention is required for the observational needs of the study.
Study: NCT01192048

Intervention type: OTHER
Intervention: Blood Sample Collection
Description: Blood sample collection for direct sequencing, microarray, single nucleotide polymorphism, whole-genome array comparative genomic hybridization DNA analyses, and/or whole exome or genome sequencing.
Study: NCT02686736

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Internet-based educational intervention
Description: The intervention will include four educational sessions about risky sexual behaviors and its prevention. The intervention will last one month (one session per week) followed by a three-month follow-up. Teens will be allowed to access to a weekly session at any time and as often as he/she likes.
Study: NCT02774642

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBTI-PE
Description: Integrates CBT-I and PE with the goal of enhancing both insomnia and PTSD outcomes. Integrated treatment will be delivered in 14 90-minute weekly sessions. CBTI-PE starts with VA rollout CBT-I for the first 3 weeks with a focus on the effects of PTSD on insomnia. PE protocol (psychoeducation) begins on week 4 of treatment and both treatments overlap till week 6 when CBT-I ends and the active treatment of PE begins (i.e., imaginal and in-vivo exposures). However, CBT-I sleep diary review and sleep time adjustment will continue till the end of treatment to increase adherence

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hygiene-PE
Description: The investigators have included a non-active sleep control arm (3 Sessions)to allow for the dose response of 14 90 minute sessions. The non-active sleep control condition used in this study is a manualized protocol developed to exclude the active components of standard CBT-I treatment. Hygiene includes presentation of sleep hygiene education and reviewing daily stressors that may impact sleep before starting PE on week 4.
Study: NCT03727880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Following standard of care neoadjuvant chemotherapy, subjects will receive two doses of pembrolizumab (200mg) IV 3 weeks apart prior to surgery. After surgery, subjects will receive adjuvant standard of care chemotherapy. Following adjuvant chemotherapy, subjects will receive 8 doses of pembrolizumab (200mg) IV 3 weeks apart.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Following standard of care neoadjuvant chemotherapy, subjects will receive two doses of pembrolizumab (200mg) IV 3 weeks apart prior to surgery. After surgery, subjects will receive adjuvant standard of care chemotherapy. Following adjuvant chemotherapy, subjects will receive 8 doses of pembrolizumab (200mg) IV 3 weeks apart.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib
Description: Following 2 cycles of standard of care neoadjuvant chemotherapy, subjects will receive 400 mg defactinib twice a day up until 2 days preceding their surgery (approximately 6 weeks) during the immunotherapy cycles with pembrolizumab. After surgery, subjects will receive adjuvant standard of care chemotherapy. Following adjuvant chemotherapy, subjects will receive 400mg defactinib twice a day for 24 weeks.
Study: NCT03240263

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Supervised daily sessions of training including 4 sets of 6-10 breaths using a tapared flow resistive load device\*. Resistance adjusted to the highest tolerable load.~\*Electronic Variable Flow Resistive Loading IMT Device/ POWERbreathe®KH1, HaB International Ltd., Southam, UK

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Endurance training
Description: Supervised daily sessions of training including 4 sets of 6-10 breaths using a tapared flow resistive load device\*. Low training resistance adjusted to \<10% maximal inspiratory pressure.~\*Electronic Variable Flow Resistive Loading IMT Device/ POWERbreathe®KH1, HaB International Ltd., Southam, UK
Study: NCT03819894

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Introduction of a lower female hs-cTn threshold
Description: The new female hs-cTn threshold will be baed on current recommendations for each of the assays used (hs-cTn T and I). The hospitals are the unit of randomization. At 5-month intervals, randomly selected hospitals will be advised that they are to transition to the intervention phase. For all men, the standard of care, overall population threshold will be used throughout the entire study.
Study: NCT04127799

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subjects with AF conventional treatment
Description: Subjects with standardized treatment according to latest guidelines via conventional visit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Subjects with AF conventional treatment
Description: Subjects with standardized treatment according to latest guidelines via conventional visit.
Study: NCT01779869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: Regadenoson 400 micrograms will be administered in a single IV bolus (\<10 seconds) via an antecubital cannula and followed by 5 mL of saline flush. 10-20 seconds after the regadenoson is administered, 10 mCi of 13N-ammonia as a bolus, and 0.075 mmol/Kg of gadobenate dimeglumine MR contrast agent at a rate of 5 mL/sec followed by a 15 mL normal saline flush will be administered simultaneous, each into an antecubital vein, and a 15 min list-mode PET acquisition will be acquired simultaneously with the MR perfusion imaging.
Study: NCT04348019

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Fasting
Description: Fasting was defined as no foods or caloric beverages.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Fasting was defined as no foods or caloric beverages.
Study: NCT03837665

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Platelet Rich Plasma (PRP) is blood plasma that has been enriched with platelets.
Study: NCT02794987

Intervention type: DEVICE
Intervention: SpyGlass® choledoscopy
Description: Stage 1: patients included were evaluated using a standard duodenoscope and both SpyGlass® cholangioscopes: First generation, SpyGlass® Direct Visualization System and Second generation, Digital SpyGlass® DS System (Boston Scientific, Marlborough, Massachusetts, USA) Procedures were performed by one experienced endoscopists with more than 300 ERCP/year (C.R.M). Biopsies were taken in order to correlate to histopathology. Stage 2: patients will be evaluated using a standard duodenoscope and second generation, Digital SpyGlass® DS System (Boston Scientific, Marlborough, Massachusetts, USA). Procedures will be performed by two experienced endoscopists with more than 300 ERCP/year (C.R.M and M.S.A). Biopsies will be taken in order to correlate to histopathology.

Intervention type: DEVICE
Intervention: SpyGlass® choledoscopy
Description: Stage 1: patients included were evaluated using a standard duodenoscope and both SpyGlass® cholangioscopes: First generation, SpyGlass® Direct Visualization System and Second generation, Digital SpyGlass® DS System (Boston Scientific, Marlborough, Massachusetts, USA) Procedures were performed by one experienced endoscopists with more than 300 ERCP/year (C.R.M). Biopsies were taken in order to correlate to histopathology. Stage 2: patients will be evaluated using a standard duodenoscope and second generation, Digital SpyGlass® DS System (Boston Scientific, Marlborough, Massachusetts, USA). Procedures will be performed by two experienced endoscopists with more than 300 ERCP/year (C.R.M and M.S.A). Biopsies will be taken in order to correlate to histopathology.